Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytokine-activated natural killer cells
- Development stage
- Unknown
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intraperitoneal, Intratumoral
01
Overview
Cytokine-activated natural killer (NK) cells are an adoptive cellular immunotherapy involving the ex vivo expansion and activation of NK cells using specific cytokines, such as Interleukin-2 (IL-2), Interleukin-12 (IL-12), Interleukin-15 (IL-15), or Interleukin-18 (IL-18). This process enhances the cells' proliferative capacity, survival, and cytotoxic effector functions against malignant or virally infected cells. Unlike CAR-NK cells, these are typically non-genetically modified and rely on their natural repertoire of activating receptors (e.g., NKG2D, NKp30, NKp44, NKp46) and the release of cytotoxic granules containing perforin and granzymes to induce target cell apoptosis. They are investigated for the treatment of various solid tumors, hematologic cancers, and chronic viral infections like Hepatitis C and Cytomegalovirus.
- Other names
- cytokine-induced natural killer cellsactivated NK cellsNK cells, cytokine-activated
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on cytokine-activated natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytokine-activated natural killer cells.